KEYNOTE-F49, NCT05763004: A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors |
|
|
| Recruiting | 1 | 140 | RoW | IOS-1002, IOS-1002 + KEYTRUDA® (pembrolizumab) | ImmunOs Therapeutics AG, Merck Sharp & Dohme LLC | Solid Tumor, Adult | 05/24 | 03/25 | | |
